Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Claims for Health Damage Compensation Continued to Increase in FY2015, Rising to 1,566: PMDA
December 22, 2016
- Blanket Driving Ban for 3 SNRIs Eased: MHLW
December 21, 2016
- MHLW Begins Drafting Manual on Proper Use of Antibiotics for Clinicians
December 21, 2016
- Quarterly Price Reviews for Indication-Added Drugs Likely to Get Underway in FY2017, Annual Scheme in FY2018: Officials
December 21, 2016
- Four Ministers Map Out Basic Policy for Drug Pricing Revamp
December 21, 2016
- Basic Policy for Drastic Reform of Drug Pricing System
December 20, 2016
- MHLW OKs Tecfidera, Otezla, Other Drugs
December 20, 2016
- Natural Rise in Social Security Spending to Be Curbed to 500 Billion Yen
December 20, 2016
- Govt Clarifies Its Goals in Healthcare R&D Plan, Aims to Begin Clinical Trials for iPS-Based Therapies by 2020
December 19, 2016
- Chuikyo Kicks Off Debates on 2018 Dual Reform of Healthcare and Long-Term Care Insurance
December 15, 2016
- HIV Med Descovy OK’ed for NHI Price Listing on Dec. 21
December 15, 2016
- PD-L1 Expression Testing Won’t Be a Must for Opdivo, but Clarification Needed: Chuikyo
December 15, 2016
- MHLW Drafts Optimal Use Guidelines for Opdivo in NSCLC
December 14, 2016
- Diet members Aim to Create Non-Partisan Forum for Healthcare Industry
December 14, 2016
- Survey Method, Product Scope for Annual Revisions to Be Discussed in 2017
December 14, 2016
- LDP Health Panel Chair Submits Letter Opposing Annual Price Revisions
December 13, 2016
- PMDA Reviewing Risk of Hep B Virus Reactivation for Revlimid
December 13, 2016
- MHLW Announces 16 APIs as Candidates for Switch-OTC Status: None for Lifestyle Diseases
December 13, 2016
- MHLW Panel Recommends 3 Products Including Talion for Approval as “Behind-the-Counter Drugs”
December 13, 2016
- Balance between Survey Costs and Price Gap Important, Shiozaki Says on Annual Revisions
December 12, 2016
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…